Alnylam To Share Progress Across Its Transthyretin Amyloidosis Franchise Including Additional Analyses Of The Helios-B Phase 3 Study Results At Heart Failure 2025 Congress
RefinitivOkuma süresi: 1 dakikadan kısa
Alnylam Pharmaceuticals Inc 
ALNY:
ALNYLAM TO SHARE PROGRESS ACROSS ITS TRANSTHYRETIN AMYLOIDOSIS FRANCHISE INCLUDING ADDITIONAL ANALYSES OF THE HELIOS-B PHASE 3 STUDY RESULTS AT HEART FAILURE 2025 CONGRESS
Bu haberi okumak için giriş yapın veya sonsuza kadar ücretsiz bir hesap oluşturun